Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2016	Mar. 29, 2015
Segment Reporting Information [Line Items]
Revenues	[1],[2]	$ 13,005	$ 10,864
Net income (loss)	[1]	3,016	2,376
Certain significant items [Member]
Segment Reporting Information [Line Items]
Revenues	[3]	0	0
Cost reduction and productivity initiatives excluding acquisition related costs		137	104
Other legal matters, net		286
Impairment of intangible assets		131
Alignment Costs		51	101
Other nonoperating income (expense)		(34)	(23)
Established Products Business [Member]
Segment Reporting Information [Line Items]
Revenues	[4]	5,972	5,125
Established Products Business [Member] | CentreOne [Member] | Global Established Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	$ 188	111
Adjustment [Member] | Established Products Business [Member] | CentreOne [Member] | Global Established Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues			111
Net income (loss)			21
Global Established Pharmaceutical Research and Development [Member] | Global Established Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Costs and expenses			$ 66

[1] Amounts may not add due to rounding.

[2] On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the first quarter of 2016, but not for the first quarter of 2015. See Note 2A for additional information.

[3] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.For Earnings in the first quarter of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $137 million, (ii) charges for certain legal matters of $286 million, (iii) certain asset impairment charges of $131 million, (iv) charges for business and legal entity alignment of $51 million and (v) other charges of $34 million. For additional information, see Note 3 and Note 4.For Earnings in the first quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $104 million, (ii) charges for business and legal entity alignment of $101 million and (iii) other charges of $23 million. For additional information, see Note 3 and Note 4.

[4] The Established Products business consists of GEP, which includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in GEP’s operating results in our condensed consolidated statement of income commencing from the acquisition date of September 3, 2015. As a result, revenues for the first quarter of 2015 and GEP's revenues for the first quarter of 2015 do not include Hospira's revenues. Also, effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne, is now part of GEP. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including our manufacturing and supply agreements with Zoetis Inc. (previously known as Pfizer CentreSource or PCS); and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. Prior to 2016, PCS was managed outside our operating segments and its revenues were reported as other business activities. We have reclassified prior period PCS revenues ($111 million in the first quarter of 2015) to conform to the current period presentation as part of GEP.

[5] Pfizer CentreOne includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to our manufacturing and supply agreements with Zoetis Inc. (previously known as Pfizer CentreSource or PCS); and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation. For additional information, see (e) above.